Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -45.47% is 47% below its 5-year average of -31.02%, near the low end of its 5-year range (-50.51%–-15.81%).
69.38% below its 12-month average of -26.84%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.11%.
RETURN ON ASSETS (ROA)
-45.47%
RETURN ON ASSETS (ROA) AVG TTM
-26.84%
RETURN ON ASSETS (ROA) AVG 3Y
-30.13%
RETURN ON ASSETS (ROA) AVG 5Y
-31.02%
RETURN ON ASSETS (ROA) AVG 10Y
-32.98%
RETURN ON ASSETS (ROA) AVG 15Y
-33.47%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-69.38%
CURRENT VS 3Y AVG
-50.91%
CURRENT VS 5Y AVG
-46.59%
CURRENT VS 10Y AVG
-37.88%
CURRENT VS 15Y AVG
-35.85%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-41.04%
vs the sector median at left
Neurogene Inc.
Market Cap
$402.17M
Return on Assets (ROA)
-45.47%
TTM Avg
-26.84%
3Y Avg
-30.13%
5Y Avg
-31.02%
Market Cap
$404.24M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
Market Cap
$405.74M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$406.58M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$396.31M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$415.98M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$412.30M
Return on Assets (ROA)
12.09%
TTM Avg
1.03%
3Y Avg
-6.34%
5Y Avg
-7.45%
Market Cap
$411.21M
Return on Assets (ROA)
-62.39%
TTM Avg
-45.13%
3Y Avg
-56.85%
5Y Avg
-56.85%
Market Cap
$397.99M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neurogene Inc. (NGNE) | $402.17M | -45.47% | -26.84% | -30.13% | -31.02% |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | -17.62% | -32.09% | -24.12% | -19.05% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | -71.16% | -43.23% | -31.68% | -18.72% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | -41.33% | -54.52% | -54.52% | -54.52% |
| Shoulder Innovations, Inc. (SI)vs › | $396.31M | -23.05% | -30.00% | -27.77% | -27.77% |
| Rezolute, Inc. (RZLT)vs › | $415.98M | -68.75% | -55.58% | -51.15% | -46.76% |
| Strata Critical Medical, Inc. (SRTA)vs › | $412.30M | 12.09% | 1.03% | -6.34% | -7.45% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | -62.39% | -45.13% | -56.85% | -56.85% |
| Carlsmed, Inc. (CARL)vs › | $397.99M | -30.75% | -34.79% | -68.11% | -68.11% |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | -61.86% | -66.50% | -24.17% | -122.74% |
ROA
-45.5%
ROE
-51.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -31.31% |
| 2024-12-31 | -22.38% |
| 2023-12-31 | -16.32% |
| 2022-12-31 | -50.51% |
| 2021-12-31 | -49.78% |
| 2020-12-31 | -15.81% |
| 2019-12-31 | -47.23% |
| 2018-12-31 | -40.69% |
| 2017-12-31 | -45.48% |
| 2016-12-31 | -23.97% |
| 2015-12-31 | -19.29% |
| 2014-12-31 | -57.51% |
| 2013-12-31 | -14.85% |
| 2012-12-31 | -329.39% |
| 2011-12-31 | -106.30% |
